Results 231 to 240 of about 10,899,927 (248)
Some of the next articles are maybe not open access.
p53 and cell-cycle control: a finger in every pie.
Pathologie-biologie, 2000The p53 protein plays diverse, complementary roles in the regulation of cell proliferation, genetic integrity and survival after exposure to various forms of genotoxic and non-genotoxic stresses. While there is considerable in vivo evidence that induction of apoptosis in response to DNA damage is an important biological response mediated by p53, the ...
S, North, P, Hainaut
openaire +1 more source
Another Slice of the Pie Uncovered: RIT1M90I Is an Actionable Driver in Non–Small Cell Lung Cancer
Cancer ResearchLung adenocarcinoma has become a paradigm for precision oncology and success with targeted therapies. However, large chunks of the pie chart of molecular drivers remain unknown, preventing many patients from similarly benefiting from this strategy. Here, we highlight the side-by-side release of two impactful studies from Mozzarelli and colleagues and ...
Cheng Pei Wu, Aria Vaishnavi
openaire +1 more source
Mechanism of asymmetric PIE-1 segregation in C. elegans one-cell embryo
2010Die Zelldifferenzierungsdeterminante PIE-1 bestimmt die Entwicklung und Identität der Keimbahn-Stammzellen in C. elegans, in dem die Transkription der Stammzellen inhibiert wird. PIE-1 akkumuliert in den asymmetrischen Zellteilungen auf einer Seite des frühen Embryos. Dieser Prozeß ermöglicht, daß PIE-1 nur an die Keimbahnzellen weitergegeben wird. PIE-
openaire +1 more source
Seminars in oncology, 1992
Ifosfamide has shown promising single-agent activity in non-small cell lung cancer (NSCLC). We combined ifosfamide (1,800 mg/m2 plus mesna 1,100 mg/m2 by intravenous [IV] continuous infusion daily for 3 days) with cisplatin (20 mg/m2 IV for 3 days) and etoposide (80 mg/m2 IV for 3 days) and treated 41 chemotherapy-naive patients with recurrent or ...
M, Shirinian +4 more
openaire +1 more source
Ifosfamide has shown promising single-agent activity in non-small cell lung cancer (NSCLC). We combined ifosfamide (1,800 mg/m2 plus mesna 1,100 mg/m2 by intravenous [IV] continuous infusion daily for 3 days) with cisplatin (20 mg/m2 IV for 3 days) and etoposide (80 mg/m2 IV for 3 days) and treated 41 chemotherapy-naive patients with recurrent or ...
M, Shirinian +4 more
openaire +1 more source
Journal of Molecular and Cellular Cardiology, 2015
Christopher Kane, Cesare M. Terracciano
openaire +2 more sources
Christopher Kane, Cesare M. Terracciano
openaire +2 more sources
P26 Some in cell machines developed for destructive PIE
1981J. Bowen, M. D. Jepson
openaire +1 more source
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2015
openaire +1 more source
openaire +1 more source

